MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, published by TAYLOR & FRANCIS LTD, is a premier academic journal dedicated to advancing our understanding of receptor biology and signal transduction mechanisms. With an ISSN of 1079-9893 and an E-ISSN of 1532-4281, this journal has maintained a reputable standing since its inception in 1980, continually addressing pivotal topics in biochemistry, cell biology, and molecular biology. As evidenced by its 2023 Scopus rankings, which place it in the 64th percentile for Biochemistry and Genetics and Molecular Biology, JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION remains a vital source for cutting-edge research, providing insights that are essential for both academic and practical applications. Although the journal currently offers limited open access options, it stands out in the Q2 and Q3 quartiles of its respective categories, making it an invaluable resource for researchers, professionals, and students aiming to stay abreast of the latest findings and methodologies in receptor and signaling research. The journal's commitment to disseminating high-quality research underscores its significance within the scientific community, fostering innovation and collaboration across disciplines.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

BIOSCIENCE REPORTS, published by Portland Press Ltd, is a prestigious journal dedicated to advancing the fields of biochemistry, biophysics, cell biology, and molecular biology. Founded in 1981, the journal has established itself as a vital resource for researchers and professionals, boasting a significant impact factor and high rankings within its categories, including Q2 in Biochemistry and Q1 in Biophysics as of 2023. The journal’s commitment to high-quality, peer-reviewed research ensures that it remains an influential platform for the dissemination of cutting-edge scientific findings. While it operates under a traditional subscription model, it offers various access options to accommodate the needs of the scientific community. With ongoing publication through 2024, BIOSCIENCE REPORTS continues to play a crucial role in shaping discussions in the life sciences and fostering innovative research in biology.

Welcome to the Korean Journal of Physiology & Pharmacology, a pivotal academic platform dedicated to advancing the disciplines of physiology and pharmacology. Published by the esteemed Korean Journal of Physiology & Pharmacology, this journal has been disseminating valuable research findings since its inception in 1997 and continues to be a critical resource for researchers, professionals, and students in South Korea and beyond. With an ISSN of 1226-4512 and E-ISSN of 2093-3827, it offers insights into various aspects of drug action and physiological mechanisms. Although this journal currently does not subscribe to Open Access, it plays a vital role in bridging the gap between experimental and clinical studies, receiving commendations for its quality. In the 2023 Scopus rankings, it is notably positioned in the Q3 quartile for Pharmacology and Q4 for Physiology, reflecting its commitment to excellence. As the journal converges towards its comprehensive coverage in 2024, it remains a cornerstone for those looking to engage deeply with critical developments in these fields.

Chemical Biology Letters is a prominent academic journal dedicated to the evolving field of biochemistry and its applications in medical and clinical contexts. Published by ScienceIn Publications, this journal serves as a vital platform for researchers, professionals, and students alike, showcasing cutting-edge findings and innovations that drive forward our understanding of chemical interactions in biological systems. With its scope ranging from molecular biology to clinical biochemistry, Chemical Biology Letters is committed to advancing knowledge and fostering collaboration within the scientific community. Recognized for its quality, the journal is categorized in Q4 for Biochemistry and Molecular Biology fields, while achieving notably higher ranks in Medical Biochemistry, reflecting its significant contributions to the discipline. Aiming to remain accessible to a diverse audience, the journal is published in open access format, inviting researchers worldwide to explore and share invaluable insights. Established in 2014, it continues to grow in impact and relevance, paving the way for advancements in both theoretical and applied research within the realm of chemical biology.

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Protein & Cell, published by Oxford University Press, is a distinguished international journal focusing on cutting-edge research in the fields of biochemistry, biotechnology, cell biology, and drug discovery. This open access journal, active since 2014, is dedicated to disseminating innovative findings that advance our understanding of protein functions and cellular processes, making it an essential resource for researchers, professionals, and students alike. With an impressive 2023 impact factor reflected in its Q1 ranking across multiple categories such as Biochemistry, Drug Discovery, and Cell Biology, 'Protein & Cell' stands at the forefront of scientific research, driving collaboration and discussion in the scientific community. Researchers can access the journal freely online, fostering a global exchange of knowledge and contributing to significant advancements in medicine and biotechnology. Located in the United Kingdom, the journal strives to be a pivotal platform for impactful research that influences future studies and applications.

BMC Molecular and Cell Biology is a forward-thinking open-access journal published by BMC, specializing in the vital fields of molecular biology and cell biology. Since its inception in 2019, the journal has carved a niche for itself, ranking in the Q3 quartile in both Cell Biology and Molecular Biology categories as of 2023. With an ISSN of N/A and an E-ISSN of 2661-8850, the journal provides a platform for groundbreaking research, high-quality reviews, and innovative methodologies. Situated in the United Kingdom, BMC Molecular and Cell Biology promotes a diverse range of studies, addressing fundamental questions in biology that resonate with both experts and new researchers alike. The journal's commitment to open access ensures that valuable findings are readily available to the global scientific community, fostering collaboration and knowledge-sharing across disciplines. Researchers aiming to contribute to the field of cell and molecular biology will find this journal an indispensable resource for both publishing and staying informed on the latest advances.